Subhro Mallik
Executive Vice President and
Head of Life Sciences, Infosys
Life sciences companies have always been in the business of breakthroughs.
What sets this industry apart is the pairing of its relentless pursuit of new discovery with the deeply human mission behind it: to heal, restore, and improve lives. Researchers, scientists, and executives in life sciences organizations carry out this mission with intensity. They know their work touches individuals and families in profound personal ways.
Read furtherSubhro Mallik
Executive Vice President and
Head of Life Sciences, Infosys
Life sciences executives believe breakthroughs will keep coming. They expect their own companies, and the industry overall will continue discovering new drugs and ways to treat patients. This is according to a survey of 150 life sciences executives conducted for this research journal.
Read furtherArtificial intelligence (AI) is accelerating drug discovery through capabilities such as large-scale triage of promising compounds, which reduces failures and identifies strong candidates faster.
Well-governed, open, and federated data infrastructures are prerequisites for AI to be clinically useful and equitable.
Trustworthy AI with explainable models, continuous validation, and clear regulation is essential to translate computational promise into safer, fairer medicines.
Clinical trials are costly, lengthy, and failure prone, with nearly 90% of drugs trialed never reaching the market.
Trial-specific innovations related to artificial intelligence are reshaping every stage of the trial process.
Organizations that try to bolt AI on to an outdated operating model struggle to scale.
Robust data governance, human oversight, and organization culture changes can lead to more efficient and successful drug trials.
A split between life sciences CRM providers, Salesforce and Veeva, is forcing organizations to choose between platforms and prompting a rethink of engagement architecture.
CRM is evolving from a sales tool to an enterprise-wide engagement platform supporting personalized, multichannel interaction between drug developers, healthcare professionals, patients, and payers.
AI and regulation are reshaping the CRM landscape, making platform selection a strategic choice.
Amid geopolitical volatility, resilience, agility, and speed of life science supply chains matter as much as cost.
Companies must rebalance operations to reduce risk and bring production closer to customers. Advanced technologies can help offset additional costs. End-to-end visibility is essential. AI and enhanced data access must now be at the core of supply chain management.
Mergers and acquisitions (M&A) in life sciences are driven by acquiring capabilities in higher-margin areas as patents on blockbuster drugs expire.
Value creation relies on effective post-deal IT integration.
Companies need a repeatable IT integration playbook.
The move to patient-centered healthcare is changing operating models.
Personalization demands new approaches to drug development, marketing, and relationship management.
Data management and privacy are emerging as key issues.
